HLS Therapeutics (TSE:HLS) Hits New 1-Year Low at $3.25

Shares of HLS Therapeutics Inc. (TSE:HLS) hit a new 52-week low during trading on Tuesday . The company traded as low as C$3.25 and last traded at C$3.50, with a volume of 812 shares traded. The stock had previously closed at C$3.35.

Analyst Upgrades and Downgrades

HLS has been the topic of several research analyst reports. Stifel Nicolaus lowered their price objective on shares of HLS Therapeutics from C$4.15 to C$3.75 in a research note on Friday, May 10th. Raymond James decreased their price target on shares of HLS Therapeutics from C$5.00 to C$4.00 in a research report on Friday, May 10th.

HLS Therapeutics Price Performance

The company has a market cap of C$116.11 million, a P/E ratio of -3.12 and a beta of 1.14. The stock has a 50-day simple moving average of C$3.87 and a 200 day simple moving average of C$4.05. The company has a debt-to-equity ratio of 99.86, a quick ratio of 1.01 and a current ratio of 1.56.

HLS Therapeutics (TSE:HLS) last issued its earnings results on Thursday, May 9th. The company reported C($0.26) EPS for the quarter, missing analysts’ consensus estimates of C($0.25) by C($0.01). The firm had revenue of C$16.82 million during the quarter, compared to analyst estimates of C$19.61 million. HLS Therapeutics had a negative net margin of 45.81% and a negative return on equity of 26.78%. On average, equities analysts expect that HLS Therapeutics Inc. will post -0.12 EPS for the current year.

About HLS Therapeutics

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.